« Back
Home /
Tivumecirnon

Tivumecirnon

Item no.	HY-148494-1ea
Manufacturer	MedChem Express
CASRN	2174938-78-2
Amount	1 ea
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.85
Citations	[1]Hilary Plake BECK, et al. Chemokine receptor modulators and uses thereof. WO2018022992.<br>[2]Adam Grant, et al. Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475. Cancer Res 15 March 2024; 84 (6_Supplement): 2485.
Smiles	C[C@H](C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(N4CC([C@H]5CCCN(C5)CCO)C4)=CN=C3C(C(F)(F)F)=N2
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	FLX475
Available
Product Description	Tivumecirnon (FLX475) is an orally active CCR4 antagonist that blocks regulatory T cells from entering the tumor microenvironment, thereby reducing their interference with effective anti-tumor immune responses. Tivumecirnon has antitumor activity[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	543.41
Clinical_Information	Phase 2
Manufacturers Research_Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturers Target	CCR
Pathway	GPCR/G Protein; Immunology/Inflammation
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 ea

available

Request delivery time